Voor zorgverleners

Efficacy and safety of dupilumab in patients with PN with or without a history of atopic comorbidities

DUPIREAL: Two-Year Turning Point with Dupilumab in CRSwNP

The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.^1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.^2,3

Real-World Evidence and Phase IV studies in CRSwNP

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life (QoL), often requiring recurring systemic corticosteroid use and repeated sinus surgery.

Atopisch Eczeem bij kinderen

Verborgen ziektelast bij EoE eerder herkennen

Mechanism of Disease

Complex immune dysregulation can lead to autoimmunity and inflammation^1-6

Living with ITP

Patients reported significant quality of life (QoL) challenges related to their ITP¹

What is Immune Thrombocytopenia (ITP)?

Low platelet counts are one facet of ITP, but when we look at it from another angle, we see the multiple dimensions of ITP. ITP is a condition of complex immune dysregulation that reduces platelet counts—causing bleeding, bruising, fatigue, and other health-related quality-of-life (HRQoL) issues—while increasing inflammation and the risk of thromboembolic events (TEs).^1-5

Assessing fatigue in ITP patients

For ITP patients, several scales are available to measure and track fatigue and its impact on quality of life. These tools can help patients and healthcare providers gauge symptoms and adjust their ITP treatment accordingly.^1-4